AU2013303233C1 - Prostate specific antigen agents and methods of using same for prostate cancer imaging - Google Patents

Prostate specific antigen agents and methods of using same for prostate cancer imaging Download PDF

Info

Publication number
AU2013303233C1
AU2013303233C1 AU2013303233A AU2013303233A AU2013303233C1 AU 2013303233 C1 AU2013303233 C1 AU 2013303233C1 AU 2013303233 A AU2013303233 A AU 2013303233A AU 2013303233 A AU2013303233 A AU 2013303233A AU 2013303233 C1 AU2013303233 C1 AU 2013303233C1
Authority
AU
Australia
Prior art keywords
agent
ser
specific antigen
imaging
prostate specific
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013303233A
Other languages
English (en)
Other versions
AU2013303233A1 (en
AU2013303233B2 (en
Inventor
Guojie Ho
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Visen Medical Inc
Original Assignee
Visen Medical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Visen Medical Inc filed Critical Visen Medical Inc
Publication of AU2013303233A1 publication Critical patent/AU2013303233A1/en
Application granted granted Critical
Publication of AU2013303233B2 publication Critical patent/AU2013303233B2/en
Publication of AU2013303233C1 publication Critical patent/AU2013303233C1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/64—Fluorescence; Phosphorescence
    • G01N21/6486—Measuring fluorescence of biological material, e.g. DNA, RNA, cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU2013303233A 2012-08-15 2013-03-15 Prostate specific antigen agents and methods of using same for prostate cancer imaging Active AU2013303233C1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261683305P 2012-08-15 2012-08-15
US61/683,305 2012-08-15
PCT/US2013/032200 WO2014028057A1 (en) 2012-08-15 2013-03-15 Prostate specific antigen agents and methods of using same for prostate cancer imaging

Publications (3)

Publication Number Publication Date
AU2013303233A1 AU2013303233A1 (en) 2015-03-05
AU2013303233B2 AU2013303233B2 (en) 2018-05-17
AU2013303233C1 true AU2013303233C1 (en) 2018-08-23

Family

ID=48170795

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013303233A Active AU2013303233C1 (en) 2012-08-15 2013-03-15 Prostate specific antigen agents and methods of using same for prostate cancer imaging

Country Status (7)

Country Link
US (1) US9371362B2 (https=)
EP (1) EP2885006B1 (https=)
JP (1) JP6370785B2 (https=)
CN (1) CN104955484B (https=)
AU (1) AU2013303233C1 (https=)
CA (1) CA2882019C (https=)
WO (1) WO2014028057A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101296927A (zh) 2005-09-02 2008-10-29 Visen医药公司 生物相容的含n,n-二取代磺酰胺的荧光染料标记
WO2007136413A2 (en) 2005-12-22 2007-11-29 Visen Medical, Inc. Biocompatible fluorescent metal oxide nanoparticles
ES2658852T3 (es) 2008-01-18 2018-03-12 Visen Medical, Inc. Agentes de imaginología fluorescentes
AU2012253502C1 (en) 2011-05-09 2017-12-14 Visen Medical, Inc. Carbonic anhydrase targeting agents and methods of using same
US9375493B2 (en) 2012-03-30 2016-06-28 Visen Medical, Inc. Bacterial imaging agents and methods of using same
JP6370785B2 (ja) 2012-08-15 2018-08-08 ビセン メディカル， インコーポレイテッド 前立腺がんイメージングのための前立腺特異的抗原薬剤およびその使用方法
CN105339436B (zh) 2013-03-15 2018-05-25 文森医学公司 4,4-二取代环己基桥连七甲川花菁染料及其应用
JP6606487B2 (ja) 2013-03-15 2019-11-13 ビセン メディカル， インコーポレイテッド ｉｎｖｉｔｒｏおよびｉｎｖｉｖｏイメージングおよび検出のための置換シラキサンテニウム赤色〜近赤外蛍光色素
US9713649B2 (en) 2014-01-24 2017-07-25 The Cleveland Clinic Foundation PSMA-targeting imaging agents
CN119564879A (zh) 2015-08-18 2025-03-07 乐天医药生技股份有限公司 用于光免疫疗法的组合物、联用及相关方法
AU2016308286B2 (en) 2015-08-18 2022-04-07 Rakuten Medical, Inc. Phthalocyanine dye conjugates and their storage
EA202090776A1 (ru) * 2017-10-23 2020-07-27 Дзе Джонс Хопкинс Юниверсити Визуализирующие и радиотерапевтические агенты, нацеленные на фибробласт-активирующий белок-альфа (fapalpha)
WO2024181454A1 (ja) * 2023-02-27 2024-09-06 富士フイルム株式会社 化合物及びこれを用いた標識生体物質
JPWO2024181456A1 (https=) * 2023-02-27 2024-09-06
CN120752249A (zh) * 2023-02-27 2025-10-03 富士胶片株式会社 化合物及使用了该化合物的标记生物物质

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6174858B1 (en) * 1998-11-17 2001-01-16 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
US20060154324A1 (en) * 2005-01-07 2006-07-13 Kaohsiung Medical University Prostate-specific antigen probes for optical imaging
WO2007028163A1 (en) * 2005-09-02 2007-03-08 Visen Medical, Inc. Biocompatible fluorescent imaging agents
WO2007028037A1 (en) * 2005-09-02 2007-03-08 Visen Medical, Inc. Biocompatible n, n-disubstituted sulfonamide-containing fluorescent dye labels
WO2009092062A2 (en) * 2008-01-18 2009-07-23 Visen Medical, Inc. Fluorescent imaging agents
WO2011146143A2 (en) * 2010-05-21 2011-11-24 Ohmx Corporation Detection of cancer by assaying psa enzymatic activity

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4647447A (en) 1981-07-24 1987-03-03 Schering Aktiengesellschaft Diagnostic media
US5627027A (en) 1986-04-18 1997-05-06 Carnegie Mellon University Cyanine dyes as labeling reagents for detection of biological and other materials by luminescence methods
US5268486A (en) 1986-04-18 1993-12-07 Carnegie-Mellon Unversity Method for labeling and detecting materials employing arylsulfonate cyanine dyes
US5569587A (en) 1986-04-18 1996-10-29 Carnegie Mellon University Method for labeling and detecting materials employing luminescent arysulfonate cyanine dyes
US4981977A (en) 1989-06-09 1991-01-01 Carnegie-Mellon University Intermediate for and fluorescent cyanine dyes containing carboxylic acid groups
ES2199226T3 (es) 1992-09-04 2004-02-16 The General Hospital Corporation Polimeros biocompatibles que contienen mitades diagnosticas o terapeuticas.
US5808044A (en) 1993-01-22 1998-09-15 Pharmacia Biotech Inc. Indocarbocyanine and benzindocarbocyanine phosphoramidites
US5866679A (en) 1994-06-28 1999-02-02 Merck & Co., Inc. Peptides
DE4445065A1 (de) 1994-12-07 1996-06-13 Diagnostikforschung Inst Verfahren zur In-vivo-Diagnostik mittels NIR-Strahlung
US6127134A (en) 1995-04-20 2000-10-03 Carnegie Mellon University Difference gel electrophoresis using matched multiple dyes
US6008373A (en) 1995-06-07 1999-12-28 Carnegie Mellon University Fluorescent labeling complexes with large stokes shift formed by coupling together cyanine and other fluorochromes capable of resonance energy transfer
IT1276833B1 (it) 1995-10-09 1997-11-03 Sorin Biomedica Cardio Spa Coloranti fluorescenti della famiglia della solfo benz e indocianina
US6004536A (en) 1995-11-14 1999-12-21 Molecular Probes, Inc. Lipophilic cyanine dyes with enchanced aqueous solubilty
JP2000508709A (ja) 1996-04-19 2000-07-11 アマーシャム・ファルマシア・バイオテック・ユーケイ・リミテッド スクアラート染料類および蛍光配列決定法におけるそれらの使用
US6177404B1 (en) 1996-10-15 2001-01-23 Merck & Co., Inc. Conjugates useful in the treatment of benign prostatic hyperplasia
DE19717904A1 (de) 1997-04-23 1998-10-29 Diagnostikforschung Inst Säurelabile und enzymatisch spaltbare Farbstoffkonstrukte zur Diagnostik mit Nahinfrarotlicht und zur Therapie
US5877310A (en) 1997-04-25 1999-03-02 Carnegie Mellon University Glycoconjugated fluorescent labeling reagents
US6127333A (en) 1997-07-10 2000-10-03 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
US6391305B1 (en) 1997-09-10 2002-05-21 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
ZA9810974B (en) 1997-12-02 1999-06-03 Merck & Co Inc Conjugates useful in the treatment of prostate cancer
HRP20000367A2 (en) * 1997-12-02 2000-12-31 Merck & Co Inc Conjugates useful in the treatment of prostate cancer
US6133445A (en) 1997-12-17 2000-10-17 Carnegie Mellon University Rigidized trimethine cyanine dyes
EP1078023B1 (en) 1998-04-08 2011-01-05 Corporation Luminex Luminescent compounds
US6002003A (en) 1998-04-14 1999-12-14 Beckman Instruments, Inc. Cyanine dye activating group with improved coupling selectivity
US6592847B1 (en) 1998-05-14 2003-07-15 The General Hospital Corporation Intramolecularly-quenched near infrared flourescent probes
US6083486A (en) 1998-05-14 2000-07-04 The General Hospital Corporation Intramolecularly-quenched near infrared fluorescent probes
EP1065250B1 (en) 1999-07-02 2004-12-08 Visen Medical, Inc. New fluorescent cyanine labels containing a sulfamido linker arm
WO2001021624A1 (en) 1999-09-20 2001-03-29 Fuji Photo Film Co., Ltd. Compounds for fluorescence labeling
WO2002038190A2 (en) 2000-10-27 2002-05-16 Beth Israel Deaconess Medical Center Non-isotopic detection of osteoblastic activity in vivo using modified bisphosphonates
US6615063B1 (en) 2000-11-27 2003-09-02 The General Hospital Corporation Fluorescence-mediated molecular tomography
EP1209205A1 (en) 2000-11-28 2002-05-29 Innosense S.r.l. Improved process and method for the preparation of asymetric monofunctionalised indocyanine labelling reagents and obtained compounds
EP1221465A1 (en) 2001-01-03 2002-07-10 Innosense S.r.l. Symmetric, monofunctionalised polymethine dyes labelling reagents
US20030044353A1 (en) 2001-01-05 2003-03-06 Ralph Weissleder Activatable imaging probes
ATE536993T1 (de) 2002-01-02 2011-12-15 Visen Medical Inc Aminfunktionalisierte superparamagnetisierte nanoteilchen für die synthese von biokonjugaten
WO2003061711A2 (en) 2002-01-16 2003-07-31 Visen Medical, Inc. Chromophore probes for optical imaging
AU2003225763A1 (en) 2002-03-11 2003-09-29 Visen Medical, Inc. Optical imaging probes
WO2003102558A1 (en) 2002-06-04 2003-12-11 Visen Medical, Inc. Imaging volumes with arbitrary geometries in contact and non-contact tomography
US20060239916A1 (en) 2005-01-07 2006-10-26 Kai Licha Use of cyanine dyes for the diagnosis of proliferative diseases
JP5416970B2 (ja) 2005-09-02 2014-02-12 ビセン メディカル， インコーポレイテッド ニコチン酸及びピコリン酸誘導近赤外線蛍光団
WO2007136413A2 (en) 2005-12-22 2007-11-29 Visen Medical, Inc. Biocompatible fluorescent metal oxide nanoparticles
WO2007109364A2 (en) 2006-03-20 2007-09-27 The General Hospital Corporation Intramolecularly quenched fluorochrome conjugates and methods of use
US8221721B2 (en) 2007-02-09 2012-07-17 Visen Medical, Inc. Polycyclo dyes and use thereof
WO2008109832A2 (en) 2007-03-08 2008-09-12 Visen Medical, Inc. Viable near-infrared fluorochrome labeled cells and methods of making and using same
CN102026671B (zh) 2008-03-14 2014-09-03 Visen医药公司 整联蛋白靶向试剂及使用其的体内和体外成像方法
US8864821B2 (en) 2008-11-26 2014-10-21 Visen Medical, Inc. Methods and compositions for identifying subjects at risk of developing stent thrombosis
AU2012253502C1 (en) 2011-05-09 2017-12-14 Visen Medical, Inc. Carbonic anhydrase targeting agents and methods of using same
JP6370785B2 (ja) 2012-08-15 2018-08-08 ビセン メディカル， インコーポレイテッド 前立腺がんイメージングのための前立腺特異的抗原薬剤およびその使用方法

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6174858B1 (en) * 1998-11-17 2001-01-16 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
US20060154324A1 (en) * 2005-01-07 2006-07-13 Kaohsiung Medical University Prostate-specific antigen probes for optical imaging
WO2007028163A1 (en) * 2005-09-02 2007-03-08 Visen Medical, Inc. Biocompatible fluorescent imaging agents
WO2007028037A1 (en) * 2005-09-02 2007-03-08 Visen Medical, Inc. Biocompatible n, n-disubstituted sulfonamide-containing fluorescent dye labels
WO2009092062A2 (en) * 2008-01-18 2009-07-23 Visen Medical, Inc. Fluorescent imaging agents
WO2011146143A2 (en) * 2010-05-21 2011-11-24 Ohmx Corporation Detection of cancer by assaying psa enzymatic activity

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DRAKE CHRISTOPHER R ET AL, "Activatable Optical Probes for the Detection of Enzymes", CURRENT ORGANIC SYNTHESIS, (201108), vol. 8, no. 4, ISSN 1875-6271, pages 498 - 520 *

Also Published As

Publication number Publication date
CN104955484A (zh) 2015-09-30
US20140050662A1 (en) 2014-02-20
CA2882019A1 (en) 2014-02-20
US9371362B2 (en) 2016-06-21
WO2014028057A1 (en) 2014-02-20
JP2015532641A (ja) 2015-11-12
CN104955484B (zh) 2019-01-15
JP6370785B2 (ja) 2018-08-08
AU2013303233A1 (en) 2015-03-05
CA2882019C (en) 2021-02-09
AU2013303233B2 (en) 2018-05-17
EP2885006A1 (en) 2015-06-24
EP2885006B1 (en) 2018-08-08

Similar Documents

Publication Publication Date Title
AU2013303233C1 (en) Prostate specific antigen agents and methods of using same for prostate cancer imaging
US12110283B2 (en) Carbonic anhydrase targeting agents and methods of using same
EP2831264B1 (en) Bacterial imaging agents and methods of using same
US9999687B2 (en) Fluorescent imaging agents
EP2268317B1 (en) Integrin targeting agents and in vivo and in vitro imaging methods using the same

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 15 MAY 2018

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 15 MAY 2018

FGA Letters patent sealed or granted (standard patent)